Role of the Ras-association domain family 1 tumor suppressor gene in human cancers

Cancer Research

Volumn 65, Issue 9, 2005, Pages 3497-3508

  Agathanggelou, Angelo ^a   Cooper, Wendy N ^a   Latif, Farida ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1; RAS PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER; CANCER DIAGNOSIS; CELL CYCLE; CHROMOSOME 3P; DEMYELINATION; EARLY DIAGNOSIS; EPIGENETICS; GENE MUTATION; GENE SILENCING; METHYLATION; MICROTUBULE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVIEW; SEQUENCE HOMOLOGY; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; ANIMALS; GENES, TUMOR SUPPRESSOR; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; SEQUENCE HOMOLOGY, AMINO ACID; TUMOR SUPPRESSOR PROTEINS;

EID: 18144411303     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-4088     Document Type: Review

References (108)

1. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. Cancer Res 2000;60:6116-33.
2. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000;25:315-9.
3. Latif F, Tory K, Gnarra J, et al. Identification of the Vonhippel-Lindau disease tumor-suppressor gene. Science 1993;260:1317-20.
4. Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
5. Chen WY, Zeng XB, Carter MG, et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet 2003;33:197-202.
6. Agathanggelou A, Honorio S, Macartney DP, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001;20:1509-18.
7. Tomizawa Y, Kohno T, Kondo H, et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res 2002;8:2362-8.
8. Chan MWY, Chan LW, Tang NLS, et al. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients. Int J Cancer 2003;104:611-6.
9. Yu MY, Tong JHM, Chan PKS, et al. Hypermethylation of the tumor suppressor gene Rassf1a and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. Int J Cancer 2003;105:204-9.
10. Lusher ME, Lindsey JC, Latif F, Pearson ADJ, Ellison DW, Clifford SC. Biallelic epigenetic inactivation of the RASSF1A tumor suppressor gene in medulloblastoma development. Cancer Res 2002;62:5906-11.
11. Kim ST, Lim DS, Canman CE, Kastan MB. Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem 1999;274:37538-43.
12. Harada K, Toyooka S, Maitra A, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002;21:4345-9.
13. Lee MG, Kim HY, Byun DS, et al. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res 2001;61:6688-92.
14. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001;61:8659-63.
15. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001;93:691-9.
16. Wagner KJ, Cooper WN, Grundy RG, et al. Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer. Oncogene 2002;21:7277-82.
17. Tozawa T, Tamura G, Honda T, et al. Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients. Cancer Sci 2004;95:736-40.
18. Murray PG, Qiu GH, Fu L, et al. Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. Oncogene 2004;23:1326-31.
19. Wong N, Li L, Tsang K, Lai PBS, To KF, Johnson PJ. Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J Hepatol 2002;37:633-9.
20. Yang B, House MG, Guo M, Herman JG, Clark DP. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol 2005;18:412-20.
21. Dreijerink K, Braga E, Kuzmin I, et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A 2001;98:7504-9.
22. Morrissey C, Martinez A, Zatyka M, et al. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma. Cancer Res 2001;61:7277-81.
23. Kuroki T, Trapasso F, Yendamuri S, et al. Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma. Clin Cancer Res 2003;9:1441-5.
24. Dammann R, Takahashi T, Pfeifer GP. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene 2001;20:3563-7.
25. Endoh H, Yatabe Y, Shmizu S, et al. RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. Int J Cancer 2003;106:45-51.
26. Horiguchi K, Tomizawa Y, Tosaka M, et al. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Oncogene 2003;22:7862-5.
27. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DSB. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 2003;63:1639-43.
28. Zhang YJ, Ahsan H, Chen Y, et al. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B-1-DNA adduct levels in human hepatocellular carcinoma. Mol Carcinog 2002;35:85-92.
29. Yu J, Ni M, Xu J, et al. Methylation profiling of twenty promoter-CpG islands of genes which may contribute to hepatocellular carcinogenesis. BMC Cancer 2002;2:29.
30. Hogg RP, Honorio S, Martinez A, et al. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer 2002;38:1585-92.
31. Lo KW, Kwong J, Hui ABY, et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001;61:3877-81.
32. Astuti D, Agathanggelou A, Honorio S, et al. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours. Oncogene 2001;20:7573-7.
33. Yoon JH, Damman R, Pfeifer GP. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 2001;94:212-7.
34. Kuzmin I, Gillespie JW, Protopopov A, et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 2002;62:3498-502.
35. Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res 2002;62:3698-701.
36. Yanagawa N, Tamura G, Oizumi H, Takahashi N, Shimazaki Y, Motoyama T. Promoter hypermethylation of tumor suppressor and tumor-related genes in non-small cell lung cancers. Cancer Sci 2003;94:589-92.
37. Kim DH, Kim JS, Ji YI, et al. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 2003;63:3743-6.
38. Zhong S, Yeo W, Tang MW, Wong N, Lai PBS, Johnson PJ. Intensive hypermethylation of the CpG island of Ras association domain family 1A in hepatitis B virus-associated hepatocellular carcinomas. Clin Cancer Res 2003;9:3376-82.
39. Toyooka S, Maruyama R, Toyooka KO, et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003;103:153-60.
40. Toyooka S, Pass HI, Shivapurkar N, et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res 2001;61:5727-30.
41. Dammann R, Yang G, Pfeifer GP. Hypermethylation of the CpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001;61:3105-9.
42. Hoon DSB, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004;23:4014-22.
43. Ng MHL, Lau KM, Wong WS, et al. Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non-functional variant transcript. Br J Haematol 2003;123:637-45.
44. Galm O, Wilop S, Reichelt J, et al. DNA methylation changes in multiple myeloma. Leukemia 2004;18:1687-92.
45. Zochbauer-Muller S, Lam S, Toyooka S, et al. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer 2003;107:612-6.
46. Honorio S, Agathanggelou A, Schuermann M, et al. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients. Oncogene 2003;22:147-50.
47. Chang HW, Chan A, Kwong DLW, Wei WI, Sham JST, Yuen APW. Evaluation of hypermethylated tumor suppressor genes as tumor markers in mouth and throat rinsing fluid, nasopharyngeal swab and peripheral blood of nasopharygeal carcinoma patient. Int J Cancer 2003;105:851-5.
48. de Caceres, II, Battagli C, Esteller M, et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004;64:6476-81.
49. Topaloglu O, Hoque MO, Tokumaru Y, et al. Detection of promoter hypermethylation of multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer Res 2004;10:2284-8.
50. Krassenstein R, Sauter E, Dulaimi E, et al. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 2004;10:28-32.
51. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002;8:514-9.
52. Liu LM, Yoon JH, Dammann R, Pfeifer GP. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene 2002;21:6835-40.
53. Hoque MO, Begum S, Topaloglu O, et al. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 2004;64:5511-7.
54. Honorio S, Agathanggelou A, Wernert N, Rothe M, Maher ER, Latif F. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours. Oncogene 2003;22:461-6.
55. Koul S, Houldsworth J, Mansukhani MM, et al. Characteristic promoter hypermethylation signatures in male germ cell tumors. Mol Cancer 2002;1:8.
56. Fiegl H, Gattringer C, Widschwendter A, et al. Methylated DNA collected by tampons: a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev 2004;13:882-8.
57. Toyooka S, Suzuki M, Maruyama R, et al. The relationship between aberrant methylation and survival in non-small-cell lung cancers. Br J Cancer 2004;91:771-4.
58. Ehrlich M, Jiang GC, Fiala E, et al. Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene 2002;21:6694-702.
59. Maruyama R, Sugio K, Yoshino L, Maehara Y, Gazdar AF. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma. Cancer 2004;100:1472-7.
60. Wang J, Lee JJ, Wang L, et al. Value of p16(INK4a) and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer. Clin Cancer Res 2004;10:6119-25.
61. van Engeland M, Roemen G, Brink M, et al. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 2002;21:3792-5.
62. Dammann R, Schagdarsurengin U, Liu LM, et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 2003;22:3806-12.
63. Li J, Zhang ZQ, Dai ZY, et al. RASSF1A promoter methylation and Kras2 mutations in non small cell lung cancer. Neoplasia 2003;5:362-6.
64. Kim DH, Kim JS, Park JH, et al. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer. Cancer Res 2003;63:6206-11.
65. Reifenberger J, Knobbe CB, Sterzinger AA, et al. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 2004;109:377-84.
66. Xing MZ, Cohen Y, Mambo E, et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res 2004;64:1664-8.
67. Eckert LB, Repasky GA, Ulku AS, et al. Involvement of ras activation in human breast cancer cell signaling, invasion, and anoikis. Cancer Res 2004;64:4585-92.
68. Kuzmin I, Liu LM, Dammann R, et al. Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection. Cancer Res 2003;63:1888-93.
69. Dong SM, Sun DI, Benoit NF, Kuzmin I, Lerman MI, Sidransky D. Epigenetic inactivation of RASSF1A in head and neck cancer. Clin Cancer Res 2003;9:3635-40.
70. Cohen Y, Singer G, Lavie O, Dong SM, Beller U, Sidransky D. The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res 2003;9:2981-4.
71. Kang GH, Lee S, Kim WH, et al. Epstein-Barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol 2002;160:787-94.
72. Byun DS, Lee MG, Chae KS, Ryu BG, Chi SG. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res 2001;61:7034-3.
73. Toyooka S, Toyooka KO, Maruyama R, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther 2001;1:61-7.
74. Toyooka S, Carbone M, Toyooka K, et al. Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells. Oncogene 2002;21:4340-4.
75. Hesson L, Dallol A, Minna JD, Maher ER, Latif F. NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 2003;22:947-54.
76. Irimia M, Fraga MF, Sanchez-Cespedes M, Esteller M. CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer. Oncogene 2004;23:8695-9.
77. Chen JD, Lui WO, Vos MD, et al. The t(I;3) breakpoint-spanning involved in clear cell renal cell genes LSAMP and NOREI are carcinomas. Cancer Cell 2003;4:405-13.
78. Hesson L, Bieche I, Krex D, et al. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 2004;23:2408-19.
79. Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F, Clark GJ. RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. Cancer Res 2004;64:8688-93.
80. Kawasaki H, Taira K. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature 2004;431:211-7.
81. Reis EM, Nakaya HI, Louro R, et al. Antisense intronic non-coding RNA levels correlate to the degree of tumor differentiation in prostate cancer. Oncogene 2004;23:6684-92.
82. Li JF, Wang FL, Protopopov A. et al. Inactivation of RASSF1C during in vivo tumor growth identifies it as a tumor suppressor gene. Oncogene 2004;23:5941-9.
83. Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 2002;22:4309-18.
84. Dallol A, Agathanggelou A, Fenton SL, et al. RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res 2004;64:4112-6.
85. Chow LSN, Lo KW, Kwong J, et al. RASSF1A is a target tumor suppressor from 3p21.3 in nasopharyngeal carcinoma. Int J Cancer 2004;109:839-47.
86. Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 2000;275:35669-72.
87. Agathanggelou A, Bleche I, Ahmed-Choudhury J, et al. Identification of novel gene expression targets for the Ras association domain family I (RASSFIA) tumor suppressor gene in non-small cell lung cancer and neuroblastoma. Cancer Res 2003;63:5344-51.
88. Smith AJH, Xian J, Richardson M, Johnstone KA, Rabbitts PH, Cre-loxP chromosome engineering of a targeted deletion in the mouse corresponding to the 3p21.3 region of homozygous loss in human tumours. Oncogene 2002;21:4521-9.
89. Liu LM, Tommasi S, Lee DH, Dammann R, Pfeifer GP. Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 2003;22:8125-36.
90. CO. Vos MD, Martinez, A, Elam C, et al. A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res 2004;64:4244-50.
91. 2/M arrest. Oncogene 2004;23:8216-30.
92. Song MS, Song SJ, Ayad NG, et al. The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 2004;6:129-37.
93. Liu LY, Vo A, Liu GQ, McKeehan WL. Novel complex integrating mitochondria and the microtubular cytoskeleton with chromosome remodeling and tumor suppressor RASSF1 deduced by in silico homology analysis, interaction cloning in yeast, and colocalization in cultured cells. In vitro Cell Dev Biol Anim 2002;38:582-94.
94. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 2002;21:1381-90.
95. Khokhlatchev A, Rahizadeh S, Xavier R, et al. Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol 2002;12:253-65.
96. Graves JD, Gotoh Y, Draves KE, et al. Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1. EMBO J 1998;17:2224-34.
97. Praskova M, Khoklatchev A, Ortiz-Vega S, Avruch J. Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem J 2004;381:453-62.
98. Rabizadeh S, Xavier RJ, Ishiguro K, et al. The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death. J Biol Chem 2004;279:29247-54.
99. Hansen DV, Hsu JY, Kaiser BK, Jackson PK, Eldridge AG. Control of the centriole and centrosome cycles by ubiquitination enzymes. Oncogene 2002;21:6209-21.
100. Fajas L, Paul C, Vie A, et al. Cyclin A is a mediator of p120(E4F)-dependent cell cycle arrest in G(I). Mol Cell Biol 2001;21:2956-66.
101. Fenton SL, Dallol A, Agathanggelou A, et al. Identification of the E1A-regulated transcription factor p120(E4F) as an interacting partner of the RASSF1A candidate tumor suppressor gene. Cancer Res 2004;64:102-7.
102. 2+ pump 4b and the proapoptotic tumor suppressor Ras-associated factor 1 (RASSF1). J Biol Chem 2004;279:31318-28.
103. Vavvas D, Li X, Avruch J, Zhang XF. Identification of Norel as a potential Ras effector. J Biol Chem 1998;273:5439-42.
104. Vos MD, Martinez A, Ellis CA, Vallecorsa T, Clark GJ. The pro-apoptotic Ras effector Norel may serve as a Ras- regulated tumor suppressor in the lung. J Biol Chem 2003;278:21938-43.
105. Aoyama Y, Avruch J, Zhang XF. Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases. Oncogene 2004;23:3426-33.
106. Comincini S, Castiglioni BM, Foti GM, Del Vecchio I, Ferretti L. Isolation and molecular characterization of rasfadin, a novel gene in the vicinity of the bovine prion gene. Mamm Genome 2001;12:150-6.
107. Sakamoto-Hojo ET, Mello SS, Pereira E, et al. Gene expression profiles in human cells submitted to genotoxic stress. Mutat Res 2003;544:403-13.
108. Vos MD, Ellis CA, Elam C, Ulku AS, Taylor BJ, Clark GJ. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 2003;278:28045-51.